After four years in private hands, Bausch & Lomb may soon head back to the public market as Chief Executive Brent Saunders is setting sights on an IPO for the U.S. eye-care giant “in the next couple of years.” Saunders, a CEO of a year and a half, is also focusing on at least two other targets: growth in emerging markets and boosting the company’s pharmaceutical business. “The hidden gem of our business is our pharmaceutical business ... We’re very interested in adding more products,” he told Reuters on Thursday.
